Citius Pharma (CTXR) Flexes Muscle in Business Update. Remains Our Top Idea.
Added to Watch List November 2019 @$0.55.
Named Our Top Idea in 2020 @$1.02.Remains Our Top Idea in 2021...
Report: First Vaccines, then Antivirals. Will the Anti-Inflammatory Be the Next Success Story in...
New Report on Revive Therapeutics (RVVTF, RVV). Ushering in Advances in Anti-Inflammatory and Antioxidant Drugs, as a Tool Against Covid.
Booya. We’re up 143% With Ardelyx (ARDX) in Three Months – and That Ain’t...
Ardelyx Adds 16% to $3.82 as Wedbush Upgrades After Q4 Earnings.
Ardelyx ( NASDAQ: ARDX ) gained 35%...
Immunomedics (IMMU) $3.00 to $88, Up 29-fold, Our Second Best Idea Ever.
Interesting Charts From the Day we Discovered it.
Gilead Sciences, Inc. (Nasdaq: GILD) and Immunomedics (Nasdaq: IMMU) announced...
Lift Off! Mustang Bio (MBIO) $9.31 Jumps 4-Fold.
‘Bubble Boy’ Biotech Soars 250 Percent After Cure Announcement (Bloomberg).
(Bloomberg) -- Shares of the tiny biotechnology company...
Citius Pharma (CTXR) $1.20. Price Target Upped to $4.00 at HC Wainright.
STREET INSIDER
H.C. Wainwright analyst Vernon Bernardino raised the price target on Citius Pharmaceuticals...
ATCC Announces $87 Million Award for Project NextGen for Vaccines, from Barda.
ATCC, the world’s premier biological materials management and standards organization, today announced a five-year, $87 million award from the Biomedical Advanced Research...
The Race to Develop Therapeutics for COVID. The Small Caps Fight for a Treatment...
The Second Wave: Biopharma Players Race to Develop Therapeutics for COVID-19 (BioSPace) December 21.
Revive Therapeutics (RVTTF), RedHill BioPharma...
Revive Therapeutics (RVVTF, RVV): Updates and News Archive.
Recent Headlines
(See FDA Filing Submission at Bottom)
LIVE QUOTE
Cybin (CYBN) Announces Unprecedented Positive Phase 2 Data After Single Dose.
Conference call to discuss CYB003 interim results today, November 1, 2023 at 11:00 a.m. ET